A moncentric review of targeted therapy on overall survival in metastatic renal clear cell carcinoma

Autor:	Jean Luc Descotes, Lamia Bensaadi, Melanie Tadj, Mathieu Laramas, Jean-Louis Quesada, Mireille Mousseau, Valentin Arnoux
Rok vydání:	2013
Předmět:	Oncology Renal clear cell carcinoma Cancer Research medicine.medical_specialty business.industry medicine.medical_treatment medicine.disease Targeted therapy Renal cell carcinoma Internal medicine medicine Overall survival business Therapeutic strategy
Zdroj:	Journal of Clinical Oncology. 31:e15593-e15593
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2013.31.15_suppl.e15593
Popis:	e15593 Background: Anti-angiogenic treatment had radically modified therapeutic strategy in metastatic renal cell carcinoma (mRCC). This study is aimed to determine the overall survival (OS) improvement in clinical practice. Methods: Retrospective, monocentric and non-interventional study in mRCC diagnosed since 2000 with 2 cohorts of patients determined according to the first line treatment (targeted therapy or others treatment). Results: Between 1 January 2000 and 31 December 2010, 98 patients were included. The 2 cohorts were balanced with regard to baseline disease and demographic characteristics in particular for prognosis profiles distribution. As first line, 58 patients received targeted therapy whose 21% were treated by bevacizumab, 71% by sunitinib and 8% by temsirolimus. In non-targeted therapy cohort (n=40), 37.5% were treated by cytokines, 15% by cytotoxic chemotherapy or hormonal therapy. Patients treated with targeted therapy had a significantly longer median OS (30 months versus 13 months; p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6d953e9bddcb316dd5c74796669f178d https://doi.org/10.1200/jco.2013.31.15_suppl.e15593 Zobrazit plný text záznamu